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previous reports that showed the lowest frequency for the e4 allele
in Southern European populations (2–6). The low frequency of
the e4-frequency allele among Mediterraneans has been linked
with a decreased risk of CAD in these populations, compared to
Northern Europeans, who have the highest e4-frequency and the
highest rate for CAD in Europe.
In accord with this, we did not find a significant difference for
the Apo E gene and genotype frequencies between patients and
controls, suggesting that the e4 allele is not a strong risk factor for
early CAD in our population. The role of Apo E genotypes in the
risk of CAD has been analyzed previously (7,8).
For the e4-allele, a significantly increased frequency in patients
compared to healthy controls has been described in some but not
all studies. These discrepancies could be partly attributed to the
fact that these studies analyzed different populations worldwide,
and the e4-allele could be a risk factor in association with other
genetic or environmental factors.
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REPLY
We appreciate the comments of Batalla et al. concerning our paper
on premature coronary artery disease (CAD). The authors share
with us their data on young adults admitted with acute coronary
syndrome. They also provide follow-up information in the sub-
group with normal cholesterol compared to those with abnormal
cholesterol levels as defined by the ratio of total cholesterol to high
density lipoprotein levels. There are some similarities between
their data and ours; however, major differences exist. Similar
features include the fact that both studies evaluated young adults
age 50 years or younger. Second, both populations were high risk,
with high rates of categorical risk factors. For instance, the rate of
smoking was 73% in their study compared to 75% in our group.
The rate of hypertension was 36% and diabetes mellitus was 9% in
Batalla et al., which is similar to the 39% and 12% in our study for
those two conditions, respectively.
Hypercholesterolemia was 77% in their report. The rate of
hypercholesterolemia was 46% in our report, but the two studies
used different definitions. A comparison between the two studies is
limited by major differences in methodology and incomplete data
provided by the authors. First, their report involves exclusively
male subjects, whereas as many as 30% of our population were
young women. Second, their analysis was done by comparing two
groups based on cholesterol levels. We, in contrast, compared two
groups based on irrefutable evidence of significant CAD. Further-
more, they do not specify the time period over which the data was
collected. For this reason we do not know the frequency of
admissions for premature CAD. Next, what percent does this
represent for admissions of acute coronary syndrome?
We commend the authors for providing follow-up information
on outcomes. In their report, after 32 months’ follow-up there
were no differences in outcome between those with abnormal
compared to normal cholesterol. They conclude that the absence of
differences in outcomes represents a lack of benefit of low choles-
terol in young adults with high rates of smoking. This interpreta-
tion is similar to an earlier report by Jee et al. (1) in subjects
without previous CAD. The suggestion that low cholesterol does
not confer a benefit for secondary prevention in young adults has
important clinical implications. There are, however, other possible
explanations. This was an observational study that did not consider
the effect of treatment. It is possible that the lack of outcome
differences may be attributable to some treatment benefit in the
group with high cholesterol who were treated according to current
guidelines. This actually proves the merit of guidelines for second-
ary prevention.
Finally, a secondary explanation concerns the small sample size.
With a small sample size in each group it is possible that one
would need a much longer duration of follow-up to appreciate
differences. We do agree that, in young adults with multiple
cardiovascular risk factors, the best strategy to reduce recurrent
events in the short term should be based on managing all
Table 1. Apo E Genotype Frequencies in Patients and Controls
Apo E
Patients
(n 5 220)
Controls
(n 5 200) p
e33 174 (79%) 151 (75%) NS
e34 32 (15%) 28 (15%) NS
e44 4 (2%) 2 (1%) NS
e23 9 (4%) 18 (9%) NS
e24 1 1 NS
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modifiable risk factors, including smoking and cholesterol abnor-
malities.
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Mild Hypercholesterolemia
and Premature Heart Disease
In a recent study published in the Journal by Akosah et al. (1), the
investigators found that the presence of borderline or mild hyper-
cholesterolemia has significant effects on the development of
premature coronary heart disease.
In this way, a group of 229 male patients ,50 years of age
(mean age 43 6 5 years), who were admitted to our Coronary Care
Unit as a result of an episode of coronary disease were prospectively
studied. During the acute phase and by means of a structured
questionnaire, the presence of smoking habits, hypertension,
diabetes and dyslipemia were recorded. A physical examination
and fasting analysis were also done. Due to clinical instability or
persistent myocardial ischemia, 132 patients underwent a cardiac
catheterization. In accordance with a previous report (2) we
considered as normolipemia a total cholesterol/HDL cholesterol
ratio (Tchol/HDL) #5. Two groups were established on this
basis. To determine new coronary events, a mean follow-up of
32 6 13 months was carried out. For statistical analysis, the chi
square test and Fisher exact test were applied.
Our study was observational and did not suppose any interven-
tion in the treatment. In the acute phase we found that 160
patients (73%) were smokers; 84 (36%) presented arterial hyper-
tension; 21 (9%) had diabetes; and 181 (77%) had dyslipemia. In
the follow-up, 45 patients (20%) retained smoking habits; 76
(34%) had arterial hypertension; 22 (10%) had diabetes; and 172
(75%) had dyslipemia.
The distribution of coronary lesions in the patients who under-
went a cardiac catheterization were: normal coronariography, 13
patients (10%); one vessel, 49 patients (37%); two vessels, 42
patients (32%); and three vessels, 28 patients (21%).
No differences were found in the prevalence of smoking habits
(93% of our patients were smokers) and diabetes in either group
(Tchol/HDL $5 vs. Tchol/HDL ,5) (3).
Nor were there any differences in the appearance of angina,
myocardial infarction, heart failure, mortality and the need for
coronary revascularization in the follow-up period. Significant data
are shown in Table 1.
We concluded that our patients, who were younger than 50
years of age, with ischemic heart disease, and who showed a
Tchol/HDL ratio #5, present less prevalence of hypertension and
show more frequently an absence of significant coronary lesions in
comparison with those patients with an altered lipid profile.
Furthermore, no additional benefits were found in relation to new
coronary events (fatal and nonfatal). We interpret that this lack of
benefit might be due to the high percentage of smokers in both
groups. Finally, our data are coincident with those reported
previously (4), showing that a normal lipid profile does not confer
additional benefit to smokers.
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REPLY
Batalla and colleagues found in a sample of 220 Spanish men with
coronary heart disease that frequencies of epsilon43 and epsilon44
genotypes did not differ from those among 200 age-matched
controls. In contrast, we observed in the Danish population (by
comparing genotype frequencies in 693 male patients with those
among 4,129 men sampled from the general population) that the
epsilon43 and epsilon44 genotypes compared with the wild-type
epsilon33 genotype in men predicted 40% and 60% increases in
risk of ischemic heart disease, respectively (1).
It is well established that there is a north-to-south decreasing
gradient of the epsilon4 allele frequency throughout Europe (2,3).
This is exemplified by an epsilon4 relative allele frequency of 17%
in the Danish population (1) versus 8% in the Spanish population,
as demonstrated by Batalla et al. We agree that the lower frequency
of the epsilon4 allele in Southern versus Northern Europe may
Table 1. Differences Between Normolipemic and
Hyperlipemic Patients
Tchol/HDL
<5 (n 5 39)
Tchol/HDL
>5 (n 5 190)
p
Value
Hypertension 7 (18%) 77 (40%) 0.007
Normal coronariography 6 (30%) 7 (6%) ,0.005
HDL 5 high density lipoprotein; Tchol 5 total cholesterol.
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